

Antonio C Wolff

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8968737/publications.pdf](https://exaly.com/author-pdf/8968737/publications.pdf)

Version: 2024-02-01

277
papers

44,058
citations

4492

83
h-index

1871

202
g-index

431
all docs

431
docs citations

431
times ranked

34310
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 3997-4013.	5.3	3,396
2	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2784-2795.	5.3	2,732
3	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2018, 36, 773-779.	5.3	1,607
4	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2018, 36, 2105-2122.	5.3	1,513
5	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2007, 131, 18-43.	2.6	1,379
6	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology, 2014, 32, 2959-2966.	5.3	1,109
7	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Archives of Pathology and Laboratory Medicine, 2014, 138, 241-256.	2.6	996
8	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of Pathology and Laboratory Medicine, 2010, 134, e48-e72.	2.6	877
9	Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. New England Journal of Medicine, 2008, 358, 1663-1671.	30.7	870
10	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal of Clinical Oncology, 2020, 38, 1346-1366.	5.3	771
11	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 907-922.	2.6	770
12	Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2008, 300, 2754.	7.1	750
13	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Archives of Pathology and Laboratory Medicine, 2018, 142, 1364-1382.	2.6	692
14	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine, 2015, 372, 134-141.	30.7	621
15	Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 961-965.	5.3	523
16	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine, 2016, 375, 209-219.	30.7	523
17	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Oncology Practice, 2010, 6, 195-197.	3.1	517
18	Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer. New England Journal of Medicine, 2009, 360, 2055-2065.	30.7	515

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. <i>Journal of Clinical Oncology</i> , 2008, 26, 1810-1816.	5.3	477
20	TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2615-2623.	5.3	424
21	Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2011, 29, 40-46.	5.3	375
22	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	5.3	320
23	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	5.3	306
24	Detection of Tumor <i>PIK3CA</i> Status in Metastatic Breast Cancer Using Peripheral Blood. <i>Clinical Cancer Research</i> , 2012, 18, 3462-3469.	7.3	301
25	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	5.3	272
26	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temeirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 195-202.	5.3	253
27	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2838-2847.	5.3	250
28	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	5.3	237
29	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 545-563.	2.6	222
30	Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factorâ€“Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation. <i>Journal of Clinical Oncology</i> , 2009, 27, 5911-5918.	5.3	221
31	Treatment of HER2-positive breast cancer. <i>Breast</i> , 2014, 23, 128-136.	2.3	202
32	Transitioning to Breast Cancer Survivorship: Perspectives of Patients, Cancer Specialists, and Primary Care Providers. <i>Journal of General Internal Medicine</i> , 2009, 24, 459-466.	2.8	199
33	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Updateâ€“Integration of Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2019, 37, 1956-1964.	5.3	194
34	Obesity at diagnosis is associated with inferior outcomes in hormone receptorâ€“positive operable breast cancer. <i>Cancer</i> , 2012, 118, 5937-5946.	4.1	181
35	Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence. <i>Cancer Research</i> , 2011, 71, 6195-6207.	0.9	180
36	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	10.2	180

#	ARTICLE	IF	CITATIONS
37	Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive ²³ Na MRI. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 151-160.	2.6	177
38	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	5.3	176
39	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2353-2360.	5.3	172
40	Breast Cancer Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 542-590.	5.4	163
41	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1700.	7.4	158
42	Prevention, Screening, and Surveillance Care for Breast Cancer Survivors Compared With Controls: Changes from 1998 to 2002. <i>Journal of Clinical Oncology</i> , 2009, 27, 1054-1061.	5.3	155
43	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. <i>Cancer Research</i> , 2014, 74, 2160-2170.	0.9	150
44	Long term side effects of adjuvant chemotherapy in patients with early breast cancer. <i>Breast</i> , 2015, 24, S149-S153.	2.3	150
45	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	5.3	150
46	Pharmacogenetic Pathway Analysis of Docetaxel Elimination. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 155-163.	5.0	148
47	Postoperative Mortality in Cancer Patients With Preexisting Diabetes. <i>Diabetes Care</i> , 2010, 33, 931-939.	9.3	145
48	Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese. <i>Journal of Clinical Oncology</i> , 2007, 25, 4707-4713.	5.3	144
49	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. <i>Journal of Clinical Oncology</i> , 2018, 36, 1556-1563.	5.3	143
50	Breast Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 753-761.	5.4	137
51	Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer. <i>Annals of Internal Medicine</i> , 2008, 148, 358.	9.7	135
52	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2433-2443.	5.3	134
53	Comparing Care for Breast Cancer Survivors to Non-Cancer Controls: A Five-Year Longitudinal Study. <i>Journal of General Internal Medicine</i> , 2009, 24, 469-474.	2.8	132
54	Invasive Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 136-222.	5.4	128

#	ARTICLE	IF	CITATIONS
55	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	5.3	123
56	Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1839-1851.	2.5	121
57	HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 437-441.	3.1	121
58	The Role of Informatics in Promoting Patient-Centered Care. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 211-218.	2.1	119
59	Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. <i>Journal of Clinical Oncology</i> , 2010, 28, 2418-2422.	5.3	118
60	NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-21.	5.4	114
61	Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practice. <i>Psycho-Oncology</i> , 2013, 22, 895-901.	2.5	114
62	Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, e458-e458.	5.3	113
63	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2416-2427.	5.3	113
64	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	5.3	113
65	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017, 23, 2691-2701.	7.3	112
66	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 751-758.	5.3	111
67	Older Adults' Views and Communication Preferences About Cancer Screening Cessation. <i>JAMA Internal Medicine</i> , 2017, 177, 1121.	5.2	101
68	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	6.6	101
69	The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 670-678.	5.4	100
70	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. <i>Journal of Clinical Oncology</i> , 2023, 41, 3867-3872.	5.3	100
71	Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience. <i>Journal of Clinical Oncology</i> , 2015, 33, 340-348.	5.3	99
72	Metastatic Breast Cancer, Version 1.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 821-829.	5.4	97

#	ARTICLE	IF	CITATIONS
73	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	7.3	96
74	Tumor targeting by conjugation of DHA to paclitaxel. <i>Journal of Controlled Release</i> , 2001, 74, 233-236.	10.3	95
75	Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 406-414.	6.6	91
76	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 2539-2551.	5.3	90
77	Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 3828-3834.	5.3	85
78	Primary Systemic Therapy in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 1558-1569.	5.3	85
79	Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice. <i>Supportive Care in Cancer</i> , 2007, 15, 1075-1085.	2.3	85
80	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	5.3	85
81	Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3051-3057.	5.3	84
82	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelisisb for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	7.3	83
83	A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961.	3.3	79
84	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. <i>Clinical Cancer Research</i> , 2015, 21, 2771-2779.	7.3	79
85	NCCN Invasive Breast Cancer Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 246.	5.4	77
86	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	6.6	76
87	Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3117-3125.	5.3	75
88	Quality of Care for Comorbid Conditions During the Transition to Survivorship: Differences Between Cancer Survivors and Noncancer Controls. <i>Journal of Clinical Oncology</i> , 2013, 31, 1140-1148.	5.3	75
89	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	7.4	74
90	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 731-740.	2.6	74

#	ARTICLE	IF	CITATIONS
91	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 685-693.	5.3	74
92	Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 920-927.	3.0	73
93	Monitoring of neoadjuvant chemotherapy using multiparametric, ²³ Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 119-126.	2.6	70
94	Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 806-813.	5.3	69
95	Predicting Cancer Therapy-Induced Cardiotoxicity. <i>Drug Safety</i> , 2002, 25, 301-311.	3.3	66
96	Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). <i>Breast Cancer Research and Treatment</i> , 2015, 151, 589-596.	2.6	66
97	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3171-3181.	5.3	65
98	TBCRC 008: Early Change in ¹⁸ F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	6.0	64
99	Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. <i>Cancer</i> , 2018, 124, 1904-1911.	4.1	63
100	Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. <i>European Journal of Cancer</i> , 2004, 40, 1170-1178.	3.0	62
101	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 907-914.	2.6	62
102	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2722-2729.	7.3	61
103	Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017, 2017, 1-19.	3.2	61
104	A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 915-924.	2.6	59
105	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	2.6	59
106	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2338-2348.	5.3	57
107	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	5.3	54
108	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4390-4397.	5.3	53

#	ARTICLE	IF	CITATIONS
109	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. <i>Obesity</i> , 2020, 28, 1678-1686.	3.2	52
110	A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay. <i>Clinical Breast Cancer</i> , 2015, 15, 467-472.	2.6	51
111	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 379-386.	7.3	51
112	Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear (²³ Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer. <i>Academic Radiology</i> , 2010, 17, 1477-1485.	2.4	50
113	Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination. <i>Journal of Cancer Survivorship</i> , 2015, 9, 641-649.	3.3	49
114	Symptoms, supportive care needs, and function in cancer patients: how are they related?. <i>Quality of Life Research</i> , 2008, 17, 665-677.	3.2	48
115	Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease. <i>Oncologist</i> , 2002, 7, 239-245.	4.1	47
116	Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. <i>JCO Oncology Practice</i> , 2020, 16, 665-674.	2.8	47
117	Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. <i>Journal of Clinical Oncology</i> , 2007, 25, 1677-1682.	5.3	45
118	Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy. <i>Cancer</i> , 2010, 116, 4168-4177.	4.1	45
119	Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. <i>Journal of Clinical Oncology</i> , 2016, 34, 699-705.	5.3	44
120	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 821-827.	7.3	43
121	Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. <i>Quality of Life Research</i> , 2010, 19, 837-845.	3.2	42
122	Improving an electronic system for measuring PROs in routine oncology practice. <i>Journal of Cancer Survivorship</i> , 2016, 10, 573-582.	3.3	42
123	Multiparametric and Multinuclear Magnetic Resonance Imaging of Human Breast Cancer: Current Applications. <i>Technology in Cancer Research and Treatment</i> , 2004, 3, 543-550.	2.0	41
124	A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence with Immunomodulatory Doses of Cyclophosphamide and Doxorubicin. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. <i>Human Gene Therapy</i> , 2004, 15, 313-337.	3.0	39
125	Concordance of cancer patients' function, symptoms, and supportive care needs. <i>Quality of Life Research</i> , 2009, 18, 991-998.	3.2	39
126	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	5.3	38

#	ARTICLE	IF	CITATIONS
127	Functional Impairment of Human Resident Cardiac Stem Cells by the Cardiotoxic Antineoplastic Agent Trastuzumab. <i>Stem Cells Translational Medicine</i> , 2012, 1, 289-297.	3.6	37
128	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	2.6	37
129	Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 689-702.	2.6	36
130	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. <i>Journal of Clinical Oncology</i> , 2021, 39, 3473-3484.	5.3	36
131	It's™s who you know: patient-sharing, quality, and costs of cancer survivorship care. <i>Journal of Cancer Survivorship</i> , 2014, 8, 156-166.	3.3	35
132	Breast Cancer Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005, 3, 238.	5.4	35
133	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 738-745.	7.3	34
134	The Adjuvant Treatment of HER2-Positive Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 230-239.	3.2	33
135	Older Adults's™ Preferences for Discussing Long-Term Life Expectancy: Results From a National Survey. <i>Annals of Family Medicine</i> , 2018, 16, 530-537.	2.2	33
136	NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, S-1-S-26.	5.4	33
137	Reply to E.A. Rakha et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1302-1304.	5.3	32
138	Local's™ regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	2.6	32
139	Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience. <i>Oncologist</i> , 2013, 18, 134-140.	4.1	31
140	Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. <i>Academic Radiology</i> , 2018, 25, 1405-1414.	2.4	31
141	Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population's™based study among older breast cancer patients. <i>Cancer</i> , 2018, 124, 899-906.	4.1	30
142	Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1571-1578.	5.3	29
143	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	5.3	29
144	Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1852-1860.	2.1	28

#	ARTICLE	IF	CITATIONS
145	Quality of End-of-Life Care for Patients with Advanced Cancer in an Academic Medical Center. <i>Journal of Palliative Medicine</i> , 2011, 14, 451-457.	1.2	27
146	Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 111-120.	2.6	26
147	Preferred Clinician Communication About Stopping Cancer Screening Among Older US Adults. <i>JAMA Oncology</i> , 2018, 4, 1126.	7.4	26
148	The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3024-3034.	7.3	26
149	Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole. <i>Cancer Prevention Research</i> , 2011, 4, 1993-2001.	1.6	25
150	CDK4 and CDK6 Inhibition in Breast Cancer – A New Standard. <i>New England Journal of Medicine</i> , 2016, 375, 1993-1994.	30.7	25
151	A randomized intervention involving family to improve communication in breast cancer care. <i>Npj Breast Cancer</i> , 2021, 7, 14.	5.4	25
152	Enhancing Therapeutic Decision Making When Options Abound: Toxicities Matter. <i>Journal of Clinical Oncology</i> , 2014, 32, 1990-1993.	5.3	24
153	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	6.6	24
154	DNA Methylation Markers for Breast Cancer Detection in the Developing World. <i>Clinical Cancer Research</i> , 2019, 25, 6357-6367.	7.3	24
155	Crohn Disease Active Inflammation Assessment with Iodine Density from Dual-Energy CT Enterography: Comparison with Histopathologic Analysis. <i>Radiology</i> , 2021, 301, 144-151.	8.5	24
156	Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support. <i>Journal of Clinical Oncology</i> , 2006, 24, 2392-2394.	5.3	22
157	Luteinizing Hormone-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2007, 7, 455-464.	2.6	22
158	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	2.6	22
159	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). <i>Breast Cancer Research and Treatment</i> , 2021, 189, 103-110.	2.6	22
160	Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome?. <i>PLoS ONE</i> , 2014, 9, e105545.	2.4	21
161	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). <i>Radiology</i> , 2021, 301, 66-77.	8.5	21
162	Troponins for predicting cardiotoxicity from cancer therapy. <i>Lancet</i> , The, 2000, 356, 1947-1948.	12.2	20

#	ARTICLE	IF	CITATIONS
163	Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer. <i>Oncologist</i> , 2003, 8, 25-30.	4.1	20
164	Sharing in care: engaging care partners in the care and communication of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 127-136.	2.6	20
165	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.8	20
166	Estrogen Receptor: A Never Ending Story?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2955-2958.	5.3	19
167	Evaluating information prescriptions in two clinical environments. <i>Journal of the Medical Library Association: JMLA</i> , 2011, 99, 237-246.	1.7	19
168	Demographic, health, and attitudinal factors predictive of cancer screening decisions in older adults. <i>Preventive Medicine Reports</i> , 2019, 13, 244-248.	1.9	19
169	Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay. <i>Cancers</i> , 2020, 12, 2772.	3.9	19
170	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 3.	5.4	19
171	ERBB2-Low Breast Cancer—Is It a Fact or Fiction, and Do We Have the Right Assay?. <i>JAMA Oncology</i> , 2022, 8, 610.	7.4	19
172	African American Women Who Receive Primary Anthracycline- and Taxane-Based Chemotherapy for Triple-Negative Breast Cancer Suffer Worse Outcomes Compared With White Women. <i>Journal of Clinical Oncology</i> , 2009, 27, e35-e37.	5.3	18
173	Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance) Tj ETQq1.1 0.784314 rgBT	2.5	18
174	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 121-129.	2.6	18
175	Patient perspectives on chemotherapy de-escalation in breast cancer. <i>Cancer Medicine</i> , 2021, 10, 3288-3298.	2.9	18
176	With maturity comes confidence: EBCTCG tamoxifen update. <i>Lancet, The</i> , 2011, 378, 747-749.	12.2	17
177	Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 16.	5.4	17
178	Re: Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria. <i>Journal of the National Cancer Institute</i> , 2012, 104, 957-958.	6.6	16
179	Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 135-143.	2.6	16
180	Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2816-2822.	5.3	15

#	ARTICLE	IF	CITATIONS
181	Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 40-45.	2.6	15
182	Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 153-162.	2.6	15
183	Older Adults™ Preferences for When and How to Discuss Life Expectancy in Primary Care. <i>Journal of the American Board of Family Medicine</i> , 2017, 30, 813-815.	1.9	15
184	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 797-804.	5.4	15
185	Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation. <i>Npj Breast Cancer</i> , 2022, 8, 53.	5.4	15
186	The androgen receptor in breast cancer: learning from the past. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 619-621.	2.6	14
187	Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. <i>Cancer Biology and Therapy</i> , 2011, 12, 808-817.	3.7	14
188	Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 465-474.	2.6	14
189	First international TNBC conference meeting report. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 407-412.	2.6	14
190	Reply to G. Sauter et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e153-e154.	5.3	13
191	A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. <i>Human Pathology</i> , 2014, 45, 880-883.	2.4	13
192	Evolving Role of the Estrogen Receptor as a Predictive Biomarker: <i>ESR1</i> Mutational Status and Endocrine Resistance in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2950-2952.	5.3	13
193	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTO Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.6	13
194	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.8	13
195	Single-Agent Topotecan as First-Line Chemotherapy in Women with Metastatic Breast Cancer: Final Results of Eastern Cooperative Oncology Group Trial E8193. <i>Clinical Breast Cancer</i> , 2005, 6, 334-339.	2.6	12
196	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2189-2192.	5.3	12
197	Updated results from the international phase III ALTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	3.0	12
198	Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 225-230.	5.3	12

#	ARTICLE	IF	CITATIONS
199	Adjuvant Chemotherapy for Postmenopausal Lymph Node-Negative Breast Cancer: It Ain't Necessarily So. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1041-1043.	6.6	11
200	The role of ovarian ablation in the adjuvant therapy of breast cancer. <i>Current Oncology Reports</i> , 2008, 10, 27-37.	4.2	11
201	Implementing a breast cancer registry and treatment plan/summary program in clinical practice: A pilot program. <i>Cancer</i> , 2013, 119, 158-163.	4.1	11
202	Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 40-46.	2.4	11
203	How Do Older Adults Consider Age, Life Expectancy, Quality of Life, and Physician Recommendations When Making Cancer Screening Decisions? Results from a National Survey Using a Discrete Choice Experiment. <i>Medical Decision Making</i> , 2019, 39, 621-631.	2.7	11
204	Breast cancer survivorship care beyond local and systemic therapy. <i>Breast</i> , 2019, 48, S103-S109.	2.3	11
205	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	5.4	9
206	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab017.	2.8	9
207	<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab054.	2.8	9
208	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	5.4	9
209	Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1243-1253.	2.5	8
210	Breast Cancer: Noninvasive and Special Situations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1182-1207.	5.4	8
211	Coordination of Care in Breast Cancer Survivors: An Overview. <i>The Journal of Supportive Oncology</i> , 2011, 9, 210-215.	2.2	8
212	Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 415-424.	2.6	7
213	Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates. <i>BMC Cancer</i> , 2022, 22, 141.	2.6	7
214	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. <i>Clinical Breast Cancer</i> , 2022, 22, 319-325.	2.6	7
215	Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. <i>Clinical Cancer Research</i> , 2023, 29, 784-790.	7.3	7
216	Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 5118-5130.	5.3	7

#	ARTICLE	IF	CITATIONS
217	Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2001, 949, 80-88.	4.0	6
218	Still Waiting After 110 Years: The Optimal Use of Ovarian Ablation As Adjuvant Therapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4949-4951.	5.3	6
219	Complete Radiologic Response and Long-Term Survival With Use of Systemic High-Dose Methotrexate for Breast Cancer-Associated Leptomeningeal Disease. <i>Clinical Breast Cancer</i> , 2012, 12, 445-449.	2.6	6
220	Does a Picture Make a Difference? Ultrasound Guidance in the Management of the Axilla After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3367-3369.	5.3	6
221	Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches. <i>Journal of Clinical Oncology</i> , 2017, 35, 2857-2859.	5.3	6
222	Examining Generalizability of Older Adults' Preferences for Discussing Cessation of Screening Colonoscopies in Older Adults with Low Health Literacy. <i>Journal of General Internal Medicine</i> , 2019, 34, 2512-2519.	2.8	6
223	Survivorship care visits in a high-risk population of breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 701-708.	2.6	6
224	CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3977-3979.	5.3	6
225	Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 623-633.	2.6	6
226	Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. <i>JCO Oncology Practice</i> , 2022, 18, 516-519.	2.8	6
227	Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer. <i>Cancer Research Communications</i> , 2022, 2, 391-401.	1.8	6
228	Early operable breast cancer. <i>Current Treatment Options in Oncology</i> , 2000, 1, 210-220.	3.2	5
229	A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 33, 725-733.	2.9	5
230	Perceptions and needs of women with metastatic breast cancer: A focus on clinical trials. <i>Breast</i> , 2013, 22, 370-373.	2.3	5
231	Patient-reported outcomes in the Translational Breast Cancer Research Consortium. <i>Cancer</i> , 2020, 126, 922-930.	4.1	5
232	Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). <i>Npj Breast Cancer</i> , 2022, 8, .	5.4	5
233	Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment. <i>JCO Oncology Practice</i> , 2023, 19, e263-e273.	2.8	5
234	Reply to R. Bhargava et al and K. Lambein et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1857-1859.	5.3	4

#	ARTICLE	IF	CITATIONS
235	Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors. <i>Journal of Oncology Practice</i> , 2016, 12, e734-e745.	3.1	4
236	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , 2020, 15, 198.	2.8	4
237	Weight Gain after Hormone Receptor-Positive Breast Cancer. <i>Current Oncology</i> , 2022, 29, 4090-4103.	2.3	4
238	Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App. <i>JCO Oncology Practice</i> , 2023, 19, 981-989.	2.8	4
239	A method for determination of dimethyl benzoylphenyl urea(BPU) in human plasma by using LC/UV. <i>Biomedical Chromatography</i> , 2004, 18, 282-287.	1.7	3
240	Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. <i>European Journal of Cancer</i> , 2007, 43, 78-86.	3.0	3
241	Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 561-568.	2.6	3
242	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	5.3	3
243	Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer. <i>Oncologist</i> , 2003, 8, 25-30.	4.1	3
244	Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets. <i>Journal of Clinical Oncology</i> , 2023, 41, 732-735.	5.3	3
245	Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy. <i>Journal of the National Cancer Institute</i> , 2023, 115, 279-287.	6.6	3
246	Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials. <i>Breast</i> , 2023, 69, 258-264.	2.3	3
247	A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 3101-3109.	7.3	3
248	Adjuvant systemic management of early stage carcinoma of the breast. <i>Surgical Oncology</i> , 1999, 8, 93-101.	1.9	2
249	The use of anthracyclines and taxanes for adjuvant therapy of breast cancer. <i>Breast</i> , 2001, 10, 90-95.	2.3	2
250	Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 303-307.	8.1	2
251	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 828, 41-54.	2.4	2
252	Detection of circulating tumor cells in the cerebrospinal fluid: A new frontier. <i>Cell Cycle</i> , 2012, 11, 203-204.	2.8	2

#	ARTICLE	IF	CITATIONS
253	Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 485-488.	3.1	2
254	Reply to C. Murray et al and V. Martin et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 3524-3525.	5.3	2
255	Late effects in a high-risk population of breast cancer survivors. <i>Supportive Care in Cancer</i> , 2022, 30, 1749-1757.	2.3	2
256	Abstract S3-03: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer. <i>Cancer Research</i> , 2015, , .	0.9	2
257	Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening?. <i>Annals of Internal Medicine</i> , 2008, 149, 357.	9.7	1
258	Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez). <i>Current Breast Cancer Reports</i> , 2011, 3, 1-3.	1.1	1
259	Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches. <i>Journal of the National Cancer Institute</i> , 2022, 114, 139-148.	6.6	1
260	Growth at 5â€‰%kPa Causes Differential Expression of a Number of Signals in a <i>Bacillus subtilis</i> Strain Adapted to Enhanced Growth at Low Pressure. <i>Astrobiology</i> , 2021, 21, 1076-1088.	3.1	1
261	Reply to I. Jatoi. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200220.	5.3	1
262	Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptorâ€“Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. <i>JCO Oncology Practice</i> , 0, , .	2.8	1
263	New data on adjuvant therapy for breast cancer. <i>Current Oncology Reports</i> , 1999, 1, 31-37.	4.2	0
264	Local failure and prognostic factors in ductal carcinoma in situ: concentration on recent publications. <i>Current Opinion in Obstetrics and Gynecology</i> , 2003, 15, 9-12.	2.2	0
265	The Clinical Benefit of Pegylated Liposomal Doxorubicin in Patients With Metastatic Breast Cancer Previously Treated With Conventional Anthracyclines: A Multicentre Phase II Trial. <i>Breast Diseases</i> , 2007, 18, 205.	0.0	0
266	Phase I/II Trial of Partial Breast Irradiation (PBI) With Various Concurrent Chemotherapy Regimens: Assessment of Skin Toxicity, Cosmetic Outcomes, and Disease Recurrence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S219-S220.	0.9	0
267	Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors. <i>Breast Diseases</i> , 2015, 26, 355-358.	0.0	0
268	Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little. <i>Journal of Clinical Oncology</i> , 2016, 34, 2203-2205.	5.3	0
269	Cancer susceptibility genes and their potential implication regarding systemic therapy for earlyâ€“stage breast cancer. <i>Cancer</i> , 2016, 122, 178-180.	4.1	0
270	Reply to L. Del Mastro and A. Prat. <i>Journal of Clinical Oncology</i> , 2017, 35, 1139-1139.	5.3	0

#	ARTICLE	IF	CITATIONS
271	Abstract P2-08-15: Clinical, pathologic, and molecular associations of tumor mutational burden in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-08-15-P2-08-15.	0.9	0
272	Flashback Foreword: Multigene Predictor for Chemotherapy Response in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 3563-3564.	5.3	0
273	Evaluation of PREDICT: a prognostic risk tool, after diagnosis of a second breast cancer. <i>JNCI Cancer Spectrum</i> , 0, , .	2.8	0
274	Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study. <i>Npj Breast Cancer</i> , 2024, 10, .	5.4	0
275	ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	5.3	0
276	Moderators of Intervention Efficacy in the Pathways to Wellness Trial of Survivorship Education and Mindfulness Meditation for Younger Breast Cancer Survivors. <i>JCO Oncology Practice</i> , 0, , .	2.8	0
277	Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. <i>Journal of Clinical Oncology</i> , 0, , .	5.3	0